Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Label "Highlights" Under FDA Rule Could Yield Inconsistencies - Merck

Executive Summary

Information included in the "Highlights" summary section of drug labeling under FDA's proposed rule would likely be inconsistent from product to product, Merck said in comments on FDA's proposed labeling rule.
Advertisement

Related Content

Physician Labeling Rule Could Save Up To $443 Mil. Over 10 Years – FDA
Physician Labeling Rule Could Save Up To $443 Mil. Over 10 Years – FDA
Labeling Format Differentiation Minimized By Rule Implementation Timeline
Labeling Format Differentiation Minimized By Rule Implementation Timeline
Labeling “Highlights” To Depend On Data In Relation To Clinical Setting
Labeling “Highlights” To Depend On Data In Relation To Clinical Setting
DTC Guidance Should Include “Consumerized” Risk Terms, AstraZeneca Says
FDA Labeling Proposal Should Allow "Flexible" Warnings, Merck Tells Agency
Indication, Warning Summaries In Labeling "Highlights" - FDA Rule
Indication, Warning Summaries In Labeling "Highlights" - FDA Rule
Advertisement
UsernamePublicRestriction

Register

PS037675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel